ATR inhibitors are a class of experimental cancer drugs designed to disable a protein that tumor cells depend on to survive the constant DNA damage they inflict on themselves through rapid, error-prone replication. Several compounds are in early- to mid-stage clinical trials, and while no ATR inhibitor has yet received regulatory approval, responses in specific patient subgroups have been striking enough to keep the field moving aggressively forward. The biology behind these drugs is rooted in one of cancer’s fundamental vulnerabilities: the very genetic chaos that drives tumor growth also leaves cancer cells uniquely exposed when their emergency repair systems are shut down.
What ATR Does in Normal Cells
Every time a cell copies its DNA before dividing, there is a risk that something will go wrong. Strands can stall, break, or tangle. ATR (short for ataxia telangiectasia and Rad3-related) is a kinase, an enzyme that adds chemical tags to other proteins to switch them on or off. Its job is to sense trouble at the replication fork, the molecular machinery that unzips and copies DNA, and coordinate the cell’s response. ATR helps pause the cell cycle to buy time for repairs, prevents new replication origins from firing prematurely, and stabilizes stalled forks so they do not collapse into dangerous breaks.
ATR is not a background player. It is active even during normal, unstressed replication. Research using super-resolution imaging has shown that ATR monitors the amount of a protective protein called RPA that coats exposed single-stranded DNA at forks during routine copying. When replication stress increases, the volume of interaction between ATR and RPA grows, and the local crowding of ATR molecules at the fork amplifies its signaling.
1Molecular Cell. Super-resolution imaging reveals that ATR is a fork surveillance factor that limits RPA accumulation at unperturbed replication forks This means ATR is always watching, and ramps up its activity proportionally when things start to go sideways. A review in Nature Reviews Molecular Cell Biology described ATR’s role as ensuring “faithful duplication of a challenging genome,” noting that its regulation of cell cycle checkpoints, origin firing, and fork stability is crucial.2PubMed Central. The essential kinase ATR: ensuring faithful duplication of a challenging genome
Why Cancer Cells Are Especially Dependent on ATR
Healthy cells have multiple overlapping systems for dealing with DNA damage. Two of the most important kinases besides ATR are ATM and DNA-PK. ATM primarily responds to double-strand breaks, the most dangerous kind of DNA lesion, while DNA-PK helps glue broken ends back together through a process called non-homologous end joining. In a normal cell, these pathways back each other up.
Cancer cells, however, frequently lose one or more of these backup systems through mutations acquired during tumor evolution. Many cancers carry inactivating mutations in the ATM gene, or in genes like BRCA1 and BRCA2 that participate in a related repair pathway called homologous recombination. These tumors already have holes in their DNA damage safety net. On top of that, the accelerated, chaotic replication driven by oncogenes generates far more replication stress than a normal cell experiences. The result: many cancer cells lean on ATR far more heavily than healthy cells do. Block ATR in those tumors, and the accumulating damage has nowhere to go. The cells cannot fix themselves and die. This is the core principle of synthetic lethality, where two individually survivable defects combine to become lethal. A cancer cell missing ATM and then exposed to an ATR inhibitor faces a catastrophic collapse in its ability to manage DNA damage.
3PubMed. A synthetic lethal screen reveals enhanced sensitivity to ATR inhibitor treatment in mantle cell lymphoma with ATM loss-of-functionThe Drug Pipeline
Over the past decade, medicinal chemistry has produced a broad pipeline of ATR inhibitor candidates. The leading compounds that have entered clinical trials include berzosertib, ceralasertib, elimusertib, camonsertib, ART0380, and gartisertib, most of which are in Phase I or Phase II studies.4PubMed Central. Recent advances in small molecule ATR kinase inhibitors as anticancer agents Each drug reflects different design strategies to make the molecules selective for ATR (rather than hitting related kinases indiscriminately) and bioavailable enough to reach tumors at effective concentrations. The development path has involved strategic chemical modifications such as scaffold hopping and sulfoximine substitution to fine-tune how selectively these compounds bind ATR and how well they perform in the body.5PubMed. ATR inhibitors: from targeting the DNA damage response to exploiting synthetic lethality-A paradigm shift in Cancer therapy
The earliest discovery work illustrates how difficult this was. One of the early chemical series, the azabenzimidazoles, showed potent and selective inhibition of ATR in lab assays but ran into problems with drug metabolism, heart-channel toxicity risk, and efflux pumps in cells that expelled the drug before it could act.6PubMed Central. Structure-Based Drug Design of Novel, Potent, and Selective Azabenzimidazoles (ABI) as ATR Inhibitors Overcoming those pharmacological hurdles took years and explains why ATR inhibitors reached the clinic well after other DNA-damage-response drugs like PARP inhibitors.
What Monotherapy Has Shown So Far
The honest picture of ATR inhibitors used alone, without a combination partner, is mixed. There are clear signals of activity, but they are concentrated in narrow patient populations defined by specific tumor mutations or molecular features.
In the first-in-human trial of the oral ATR inhibitor elimusertib in patients with advanced solid tumors, all four patients who achieved a partial response had tumors with ATM abnormalities, whether through loss of ATM protein expression, ATM-inactivating mutations, or both. One breast cancer patient who had already failed 11 prior lines of therapy saw her target lesions shrink by more than half and remained on treatment for 349 days. The overall response rate among patients with ATM aberrations across all dose levels was about 36%.7Cancer Discovery. First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors
But another monotherapy study, using berzosertib across four molecularly defined groups of advanced solid tumors, showed more sobering results. Only patients with SDH-mutant gastrointestinal stromal tumors experienced prolonged disease control, with a median progression-free survival of 229 days. Patients in the other three groups generally progressed within four months. The drug clearly hit its target: biopsies showed reduced levels of a downstream signaling marker (phosphorylated CHK1) and increased markers of DNA damage and replication stress. Yet those biomarker changes did not translate into clinical benefit for most patients. One bright spot was a protein called SLFN11: patients whose tumors expressed SLFN11 during berzosertib treatment fared significantly better, with a hazard ratio of 0.045, meaning their risk of progression was dramatically lower than those without SLFN11 expression.8Clinical Cancer Research. A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors
The upshot is that ATR inhibitors as single agents are unlikely to work broadly. They need the right molecular context, tumors with ATM loss, SLFN11 expression, or other features that create a deep dependence on ATR signaling. This has pushed the field heavily toward combination strategies and toward better methods of identifying which patients will benefit.
Combining ATR Inhibitors with Chemotherapy
The most clinically advanced combination results involve pairing ATR inhibitors with DNA-damaging chemotherapy agents, the rationale being that chemotherapy creates the kind of replication stress that ATR normally helps cells survive. Block ATR at the same time, and the damage becomes unmanageable for cancer cells.
In a Phase I trial, berzosertib combined with carboplatin produced responses in patients whose cancers had stopped responding to platinum chemotherapy alone. One patient with advanced ovarian cancer carrying a germline BRCA1 mutation achieved a partial response despite being both platinum-refractory and resistant to PARP inhibitors, a situation where very few treatment options remain.9PubMed Central. Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors
A randomized Phase II trial in platinum-resistant high-grade serous ovarian cancer directly compared gemcitabine plus berzosertib against gemcitabine alone. The combination extended median progression-free survival from about 15 weeks to 23 weeks, with a hazard ratio of 0.57, meaning patients who received the ATR inhibitor had roughly 43% less risk of disease progression during the study period.10The Lancet Oncology. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer For a patient population with limited options, that kind of improvement is worth pursuing further.
Overcoming PARP Inhibitor Resistance
PARP inhibitors were the first DNA-damage-response drugs to achieve widespread clinical use, and they have transformed treatment for ovarian, breast, prostate, and pancreatic cancers in patients with BRCA mutations and related defects. But resistance develops, and overcoming it has become a major challenge. ATR inhibitors may be part of the answer.
One resistance mechanism involves loss of a protein called SLFN11. When cells silence SLFN11, they become resistant to PARP inhibitors. Laboratory work showed that ATR inhibition could overcome this specific type of resistance, because SLFN11-deficient cells become exclusively reliant on ATR signaling to survive under PARP-inhibitor treatment. Block ATR as well, and those resistant cells lose their last safety mechanism.11PubMed Central. Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
In pancreatic cancer models that had acquired resistance to PARP inhibitors or platinum chemotherapy, a sequential dosing strategy showed promise. Treating cells first with the ATR inhibitor ceralasertib and then with olaparib (a PARP inhibitor) restored sensitivity to olaparib. The same pattern held with a second PARP inhibitor, rucaparib: prior ceralasertib exposure resensitized resistant cells. Researchers suggested that a sequential rather than simultaneous regimen might also reduce dose-limiting toxicity, which has been a practical problem with concurrent dosing of both drug classes.12British Journal of Cancer. Sequential ATR and PARP inhibition overcomes acquired DNA damaging agent resistance in pancreatic ductal adenocarcinoma
A separate line of research in ovarian cancer explored combining ATR inhibition with AKT inhibition. The combination induced DNA damage and replication stress through accumulation of R-loops, structures where RNA hybridizes with DNA during transcription. Mechanistically, the AKT inhibitor prevented a helicase called DHX9 from being recruited to resolve those R-loops, amplifying the replication stress caused by ATR blockade.13PubMed Central. AKT1 interacts with DHX9 to Mitigate R Loop-Induced Replication Stress in Ovarian Cancer These are still preclinical findings, but they illustrate how researchers are looking beyond simple two-drug pairings to construct rational multi-target strategies.
ATR Inhibitors and the Immune System
One of the more exciting developments is that ATR inhibitors appear to prime the immune system against tumors. This is not an effect anyone initially designed them for, but it may turn out to be one of their most valuable properties.
When ATR is blocked in cancer cells, the resulting DNA damage produces micronuclei, tiny blobs of DNA that leak out of the nucleus into the cell’s cytoplasm. The cell’s innate immune sensor, a pathway called cGAS-STING, detects that cytoplasmic DNA as if it were from an invading pathogen and triggers interferon signaling. In small-cell lung cancer models, ATR inhibition activated this STING-mediated interferon response, recruited T cells to the tumor, and boosted the effectiveness of PD-L1 checkpoint immunotherapy.14PubMed Central. ATR inhibition activates cancer cell cGAS/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer
In hepatocellular carcinoma (liver cancer) models, ceralasertib combined with radiation and checkpoint immunotherapy created stronger and longer-lasting anti-tumor immune memory than radiation plus immunotherapy alone. When researchers blocked STING with a chemical inhibitor, the benefit of adding the ATR inhibitor largely disappeared, confirming that the immune activation depended on the cGAS-STING pathway.15PubMed Central. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma In mouse models, this triple combination actually prevented tumor recurrence, suggesting lasting immune memory.
Pairing ATR Inhibitors with Radiation
Radiation therapy kills cancer cells by causing DNA damage, so combining it with a drug that prevents DNA damage repair is a natural fit. ATR inhibitors have shown radiosensitizing effects across multiple laboratory settings, including in cells grown at low oxygen levels that mimic the hypoxic cores of solid tumors. These hypoxic cells are notoriously resistant to radiation, and ATR inhibition was effective at increasing radiation-induced cell killing even at very low oxygen concentrations.16British Journal of Cancer. Targeting radiation-resistant hypoxic tumour cells through ATR inhibition The effect also held when paired with carbon-ion irradiation, a more specialized form of radiotherapy used in some treatment centers.17PubMed Central. VE-821, an ATR inhibitor, causes radiosensitization in human tumor cells irradiated with high LET radiation
A Phase Ib clinical trial called PATRIOT Part C tested ceralasertib combined with palliative-dose radiation in patients with advanced cancers. Among 22 evaluable patients, 77% had tumor control within the irradiated field at last follow-up, with a median follow-up of 158 days.18Nature Communications. Tumor control and immune activation through palliative irradiation and ATR inhibition, PATRIOT Part C: a phase Ib trial These are early results from a small trial, and palliative radiation is typically given at lower doses than curative-intent treatment, so the findings need to be interpreted cautiously. But they provide evidence that the radiosensitizing effect observed in the lab does carry over into patients.
Cancers That Maintain Telomeres Through ALT
A subset of cancers keeps its chromosomes from shortening not through the usual enzyme telomerase, but through a recombination-based process called alternative lengthening of telomeres, or ALT. These ALT-positive tumors turn out to be strikingly sensitive to ATR inhibition. Blocking ATR in ALT cells disrupts the recombination that maintains their telomeres, leading to chromosome fragmentation and cell death. Importantly, this effect is highly selective: ALT-positive cancer cells are killed while ALT-negative cells are largely spared.19PubMed Central. Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors
This has clinical relevance because certain cancer types are enriched for ALT, including some sarcomas, brain tumors, and melanomas. A case report described an exceptional response to the ATR inhibitor camonsertib in a patient with ALT-positive metastatic melanoma, consistent with the preclinical prediction that ALT-positive tumors would respond well.20npj precision oncology. Exceptional response to the ATR inhibitor, camonsertib, in a patient with ALT+ metastatic melanoma Testing tumors for ALT status could become one of the biomarkers used to select patients for ATR inhibitor treatment.
How Tumors Resist ATR Inhibitors
No cancer therapy works forever, and researchers are already studying how resistance to ATR inhibitors develops. One intriguing finding involves two proteins called Cyclin C and CDK8, which are part of the machinery that regulates gene transcription by RNA polymerase II. Genome-wide screens found that losing Cyclin C or CDK8 was among the strongest genetic hits conferring ATR inhibitor resistance, in both ATM-proficient and ATM-deficient cells. The mechanism is elegant: when these proteins are absent, the cell generates fewer collisions between the transcription and replication machinery, reducing the DNA-RNA hybrid structures and replication stress that ATR inhibitors exploit. With less replication stress, the cells have less need for ATR and survive its inhibition.21Nucleic Acids Research. Loss of Cyclin C or CDK8 provides ATR inhibitor resistance by suppressing transcription-associated replication stress
Understanding resistance mechanisms early is valuable because it can inform combination strategies, sequence of treatments, and biomarker development before the drugs are widely used. If transcription-replication conflict is what makes ATR inhibitors lethal, then monitoring markers of that conflict could help predict which tumors will respond and when resistance is emerging.
Tracking Drug Activity in Patients with Liquid Biopsy
One practical challenge in developing ATR inhibitors is knowing whether the drug is reaching the tumor and doing its job. A pharmacodynamic platform developed for the Phase I trial of ART0380 uses a simple blood draw to measure DNA-damage markers in circulating tumor cells alongside normal blood cells. In patients who achieved drug exposure levels predicted to be biologically effective, the DNA damage marker γH2AX increased by up to 20% in circulating tumor cells compared to baseline, while the same marker in normal blood cells stayed flat.22Cancer Research. Abstract LB520: A pharmacodynamic platform using liquid biopsy to support dose selection for the ATR inhibitor ART0380 (IACS-030380) That selectivity, damage increasing in tumor cells but not in healthy ones from the same blood sample, is exactly what you want to see. It also provides a real-time readout for dose selection, rather than relying solely on traditional endpoints like tumor shrinkage measured weeks later on imaging.
Pediatric Cancers and the Path Forward
An area where ATR inhibitors have not yet been tested clinically but where the biological rationale is strong is childhood cancers. A multi-stakeholder analysis from the ACCELERATE consortium concluded that Ewing sarcoma, rhabdomyosarcoma, and neuroblastoma are the pediatric malignancies best suited for initial evaluation of ATR inhibitors, based on their high levels of replication stress and defects in DNA damage response pathways. The group recommended that trials should restrict monotherapy evaluation to brief exposures in a small number of patients and move rapidly to combinations. Their highlighted combination partners include PARP inhibitors and antibody-drug conjugates carrying topoisomerase I inhibitor payloads. For specific subtypes like ALK/MYCN-aberrant neuroblastoma, combinations with ALK inhibitors were also supported by preclinical data.23PubMed Central. Pathway for the Development of ATR Inhibitors in Pediatric Malignancies: An ACCELERATE Multistakeholder Analysis
The emphasis on iterative trial designs, where molecular analysis of responders and non-responders is used to refine the hypothesis for the next round, reflects a broader shift in oncology drug development. Rather than running large trials in unselected patients, the field is moving toward smaller, biomarker-driven studies that try to understand who benefits and why from the start. For a drug class whose activity depends so heavily on specific tumor biology, this approach seems particularly well suited.
How ATR Inhibitors Fit Among Other DNA Repair-Targeting Drugs
ATR is not the only DNA damage response kinase being targeted by drug developers. ATM inhibitors and DNA-PK inhibitors are also in clinical development, and the three pathways interact with each other in complex ways. Inhibiting ATM or DNA-PK, especially alongside radiation or chemotherapy, enhances cancer cell killing, particularly in tumors with BRCA1 or BRCA2 mutations.24PubMed Central. Medicinal chemistry breakthroughs on ATM, ATR, and DNA-PK inhibitors as prospective cancer therapeutics This means there is not a single “best” target in the DNA damage response; the right one depends on what mutations a given tumor carries and what other pathways remain intact.
For patients and oncologists, the practical implication is that tumor molecular profiling is becoming essential. A tumor that has lost ATM function might be a good candidate for an ATR inhibitor. A tumor with intact ATM but defective homologous recombination might respond better to a different combination. The growing toolkit of DNA damage response inhibitors creates more options, but it also demands more sophisticated matching of drug to tumor biology. That matching, through genomic testing, biomarkers like SLFN11 or ALT status, and pharmacodynamic monitoring during treatment, is where much of the work in this field is concentrated right now.